keyword
MENU ▼
Read by QxMD icon Read
search

Denosumab

keyword
https://www.readbyqxmd.com/read/29162274/maxillar-osteonecrosis-associated-to-denosumab-in-a-patient-with-systemic-mastocytosis
#1
José Darío Sánchez López, Paolo Cariati, Miguel Pérez de Perceval Tara
No abstract text is available yet for this article.
November 18, 2017: Medicina Clínica
https://www.readbyqxmd.com/read/29159783/in-vitro-study-of-the-effects-of-denosumab-on-giant-cell-tumor-of-bone-comparison-with-zoledronic-acid
#2
Isao Shibuya, Masamichi Takami, Arei Miyamoto, Akiko Karakawa, Akira Dezawa, Shigeru Nakamura, Ryutaro Kamijo
Giant cell tumor of bone (GCTB) is a locally aggressive primary bone tumor that contains numerous osteoclasts formed from marrow-derived precursors through receptor activator of nuclear factor κ-B ligand (RANKL), an osteoclast differentiation factor expressed in neoplastic cells of GCTB. Denosumab, a fully human monoclonal antibody targeting RANKL, has recently been used for the treatment of GCTB, and superior treatment effects have been reported. The aim of this work was to elucidate the mechanism of action of denosumab, and the differences between denosumab and zoledronic acid at the level of GCTB cells...
November 20, 2017: Pathology Oncology Research: POR
https://www.readbyqxmd.com/read/29154388/systematic-review-of-the-effect-of-denosumab-on-children-with-osteogenesis-imperfect-showed-inconsistent-findings
#3
Guowei Li, Yanling Jin, Mitchell A H Levine, Heike Hoyer-Kuhn, Leanne Ward, Jonathan D Adachi
Osteogenesis imperfecta (OI) is a rare, inherited disorder characterised by increased bone fragility, reduced bone mass and often short stature. Most cases are due to mutations in one of the two genes encoding collagen type-1 - COL1A1 and COL1A2 (1) - and the signs and symptoms vary substantially with the disease severity. The risk of fractures is 100 times higher than the general population, even in patients with mild OI. Bisphosphonates are the current standard pharmacotherapy for managing and treating patients with severe OI, but concerns about their long-term safety have been raised (1)...
November 20, 2017: Acta Paediatrica
https://www.readbyqxmd.com/read/29154022/the-anti-tumor-effect-of-rankl-inhibition-in-malignant-solid-tumors-a-systematic-review
#4
REVIEW
A F de Groot, N M Appelman-Dijkstra, S H van der Burg, J R Kroep
At present, accumulating evidence suggests that inhibition of receptor activator of nuclear factor kappa-B ligand (RANKL) does not only induce an increase in bone mass and strength, but also has anti-tumor effects. Denosumab, an antibody targeting RANKL, is used to treat osteoporosis and to prevent skeletal related events (SREs) in patients with bone metastases originating from solid tumors. However, expression of RANKL and its receptor activator of nuclear factor kappa-B (RANK) is not solely restricted to cells involved in homeostasis of the bone and RANKL-RANK signalling appears to play a substantial role in many other processes in the body like mammary physiology, mammary tumorigenesis and the immune system...
November 2, 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29142041/occurrence-of-serious-infection-in-patients-with-rheumatoid-arthritis-treated-with-biologics-and-denosumab-observed-in-a-clinical-setting
#5
Arthur N Lau, Matthew Wong-Pack, Rod Rodjanapiches, George Ioannidis, Sally Wade, Leslie Spangler, Akhila Balasubramanian, Nicola Pannacciulli, Celia J F Lin, Patrick Roy-Gayos, William G Bensen, Robert Bensen, Jonathan D Adachi
OBJECTIVE: Previous studies combining biologic disease-modifying antirheumatic drugs (bDMARD) to treat rheumatoid arthritis (RA) have shown an increased risk of infection. However, the risk of infection with concurrent use of denosumab, a biologic agent for the treatment of osteoporosis, and a bDMARD remains unclear. Here, we evaluated the incidence of serious and opportunistic infections in patients treated concurrently with denosumab and a bDMARD and patients treated with a bDMARD alone...
November 15, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/29123990/the-skeletal-related-events-of-denosumab-versus-zoledronic-acid-in-patients-with-bone-metastases-a-meta-analysis-of-randomized-controlled-trials
#6
Zhicai Zhang, Feifei Pu, Zengwu Shao
Objective: The meta-analysis was used to evaluate the skeletal-related events (SREs) and efficacy of denosumab versus zoledronic acid (ZA) in patients with bone metastases. Methods: The data of this meta-analysis study were searched from PUBMED, EMBASE, Cochrane Library, Web of Science with Conference Proceedings, Elsevier and China National Knowledge Infrastructure (CNKI) databases till August 2017. Two independent reviewers reviewed the reference lists of relevant articles...
November 2017: Journal of Bone Oncology
https://www.readbyqxmd.com/read/29119402/a-third-case-of-glycogen-storage-disease-ib-and-giant-cell-tumour-of-the-mandible-a-disease-association-or%C3%A2-iatrogenic-complication-of-therapy
#7
Raajiv Prasad, Jane Estrella, John Christodoulou, Geoffrey McKellar, Michel C Tchan
We report the third case of Glycogen Storage Disease type 1b (GSD 1b) with Giant Cell Tumour (GCT) of the mandible, associated with Granulocyte Colony Stimulating Factor (G-CSF) use. G-CSF in GSD 1b is indicated for persistent neutropaenia, sepsis, inflammatory bowel disease and severe diarrhoea. Our patient was 12 years old at GCT diagnosis and had been treated with G-CSF from 5 years of age. He underwent therapy with interferon followed by local resection which was successful in initial control of the disease...
November 9, 2017: JIMD Reports
https://www.readbyqxmd.com/read/29118048/rank-rewires-energy-homeostasis-in-lung-cancer-cells-and-drives-primary-lung-cancer
#8
Shuan Rao, Verena Sigl, Reiner Alois Wimmer, Maria Novatchkova, Alexander Jais, Gabriel Wagner, Stephan Handschuh, Iris Uribesalgo, Astrid Hagelkruys, Ivona Kozieradzki, Luigi Tortola, Roberto Nitsch, Shane J Cronin, Michael Orthofer, Daniel Branstetter, Jude Canon, John Rossi, Manolo D'Arcangelo, Johan Botling, Patrick Micke, Linnea La Fleur, Karolina Edlund, Michael Bergqvist, Simon Ekman, Thomas Lendl, Helmut Popper, Hiroshi Takayanagi, Lukas Kenner, Fred R Hirsch, William Dougall, Josef M Penninger
Lung cancer is the leading cause of cancer deaths. Besides smoking, epidemiological studies have linked female sex hormones to lung cancer in women; however, the underlying mechanisms remain unclear. Here we report that the receptor activator of nuclear factor-kB (RANK), the key regulator of osteoclastogenesis, is frequently expressed in primary lung tumors, an active RANK pathway correlates with decreased survival, and pharmacologic RANK inhibition reduces tumor growth in patient-derived lung cancer xenografts...
November 8, 2017: Genes & Development
https://www.readbyqxmd.com/read/29116414/effect-of-denosumab-administration-on-low-bone-mineral-density-t-score-1-0-to-2-5-in-postmenopausal-japanese-women-receiving-adjuvant-aromatase-inhibitors-for-non-metastatic-breast-cancer
#9
Katsuhiko Nakatsukasa, Hiroshi Koyama, Yoshimi Ouchi, Kouichi Sakaguchi, Yoshifumi Fujita, Takayuki Matsuda, Makoto Kato, Eiichi Konishi, Tetsuya Taguchi
Although adjuvant aromatase inhibitor (AI) therapy is widely used in postmenopausal women with hormone receptor-positive breast cancer, it is known to be associated with bone loss and increased fracture risk. Denosumab, a fully human monoclonal antibody against the receptor activator of nuclear factor-κB ligand, has been shown to protect against AI-induced bone loss. However, the efficacy of denosumab in the treatment of AI-associated bone loss has not been prospectively evaluated in Japan. We prospectively monitored bone mineral density (BMD) of the lumbar spine and bilateral femoral necks in 100 postmenopausal women with hormone receptor-positive postoperative breast cancer of clinical stage I-IIIA in whom treatment with AI as adjuvant endocrine therapy was planned or had been ongoing...
November 7, 2017: Journal of Bone and Mineral Metabolism
https://www.readbyqxmd.com/read/29113523/monoclonal-antibodies-for-treating-osteoporosis
#10
Maria Felicia Faienza, Mariangela Chiarito, Gabriele D'amato, Graziana Colaianni, Silvia Colucci, Maria Grano, Giacomina Brunetti
Osteoporosis is the most widespread skeletal disease requiring innovative therapeutic strategies for its management. The understanding of receptor activator of nuclear factor kappa-B ligand (RANKL) and sclerostin's role in bone cell biology is completely changing the therapeutic landscape. RANKL supports osteoclast formation and activity and is mainly produced by cells of osteoblastic lineage. Sclerostin, an antagonist of the Wnt pathway, has a key role in bone formation and is mainly secreted by osteocytes...
November 7, 2017: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/29111914/incidence-of-osteonecrosis-of-the-jaw-onj-in-cancer-patients-with-bone-metastases-treated-with-bisphosphonates-and-or-denosumab-some-comments-and-questions
#11
Vittorio Fusco, Maura Rossi, Iolanda De Martino, Manuela Alessio, Antonella Fasciolo, Gianmauro Numico
No abstract text is available yet for this article.
November 7, 2017: Acta Clinica Belgica
https://www.readbyqxmd.com/read/29110129/real-life-management-and-outcome-of-thyroid-carcinoma-related-bone-metastases-results-from-a-nationwide-multicenter-experience
#12
G Mazziotti, A M Formenti, M B Panarotto, E Arvat, A Chiti, A Cuocolo, M E Dottorini, C Durante, L Agate, S Filetti, F Felicetti, A Filice, L Pace, T Pellegrino, M Rodari, M Salvatori, C Tranfaglia, A Versari, D Viola, S Frara, A Berruti, A Giustina, R Giubbini
PURPOSE AND PATIENTS: The M.O.S.CA.TI. (Metastases of the Skeleton from CArcinoma of the ThyroId) is a multicenter, retrospective study investigating the real-life outcome and management of bone metastases (BM) in 143 patients (63 M, 80 F; median age 64 years, range 11-87) with differentiated thyroid carcinoma (DTC). RESULTS: Radio-active iodine (RAI) treatment was performed in 131 patients (91.6%), surgical approach and/or external radiotherapy in 68 patients (47...
November 6, 2017: Endocrine
https://www.readbyqxmd.com/read/29110035/-new-aspects-on-giant-cell-tumor-of-bone
#13
REVIEW
J Lüke, M Hasenfratz, P Möller, T F E Barth
A giant cell tumor of bone (GCTB) is one of the giant cell-rich lesions of bone and has to be differentiated from non-ossifying fibroma, aneurysmatic bone cyst, chondroblastoma, "brown tumor" and osteosarcoma containing giant cells. A hallmark of GCTB is the presence of the distinct histone 3 (H3F3A) mutation G34W and its detection either by sequencing methods or using immunohistochemistry with a novel antibody against this mutational site. Worrisome is the fact that under denosumab therapy a histological change of the lesions can be seen and there are first reports of sarcomas arising after therapy...
November 6, 2017: Der Pathologe
https://www.readbyqxmd.com/read/29105841/vertebral-fractures-following-discontinuation-of-denosumab-a-post-hoc-analysis-of-the-randomized-placebo-controlled-freedom-trial-and-its-extension
#14
Steven R Cummings, Serge Ferrari, Richard Eastell, Nigel Gilchrist, Jens-Erik Beck Jensen, Michael McClung, Christian Roux, Ove Törring, Ivo Valter, Andrea T Wang, Jacques P Brown
Denosumab reduces bone resorption and vertebral and nonvertebral fracture risk. Denosumab discontinuation increases BTMs 3 months after a scheduled dose is omitted, reaching above-baseline levels by 6 months, and decreases BMD to baseline levels by 12 months. We analyzed the risk of new or worsening vertebral fractures, especially multiple vertebral fractures, in participants who discontinued denosumab during the FREEDOM study or its Extension. Participants received ≥2 doses of denosumab or placebo Q6M, discontinued treatment, and stayed in the study ≥7 months after the last dose...
November 4, 2017: Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research
https://www.readbyqxmd.com/read/29103161/multiple-vertebral-osteonecroses-k%C3%A3-mmell-s-disease-after-10%C3%A2-years-on-denosumab-is-osteocyte-apoptosis-to-blame
#15
Yves Maugars, Géraldine Bart, Pascale Guillot, Marguerite Chemel-Mary, Joëlle Glémarec, Mélanie Gahier-Penhoat, Benoit Le Goff, Christelle Darrieutort-Laffite
We report here a case of multiple vertebral osteonecroses with intrasomatic gaseous dissection (Kümmell's disease) occurring 1 year after the end of a 10-year course of denosumab treatment for osteoporosis without fractures. Histomorphometry and bone remodeling markers revealed major bone resorption and the persistence of an inhibition of bone formation. The presence of multiple empty lacunae in the bone provided evidence for high levels of osteocyte apoptosis. Osteocytes direct bone resorption (via the RANK/RANK-L/osteoprotegerin system) and formation (Wnt system, with SOST and DKK1) pathways...
November 4, 2017: Calcified Tissue International
https://www.readbyqxmd.com/read/29102242/rapid-onset-of-osteonecrosis-of-the-jaw-in-patients-switching-from-bisphosphonates-to-denosumab
#16
Noam Yarom, Towy Sorel Lazarovici, Sara Whitefield, Tal Weissman, Oshri Wasserzug, Ran Yahalom
OBJECTIVE: The aim of this study was to determine whether osteonecrosis of the jaw (ONJ) developed more rapidly in patients who switched from bisphosphonates (BP) treatment to denosumab than in patients who received only denosumab. STUDY DESIGN: This was a retrospective cohort study conducted at a tertiary referral center. Thirty-one patients with ONJ met the inclusion criteria. RESULTS: Twenty-two patients who had been on BP were switched to denosumab (BP + D), whereas 9 patients received only denosumab...
September 28, 2017: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
https://www.readbyqxmd.com/read/29101848/human-fc-receptor-like-5-distinguishes-igg2-disulfide-isoforms-and-deamidated-charge-variants
#17
Oyeleye Alabi, Jessica Dement-Brown, Mate Tolnay
Human Fc receptor-like 5 (FCRL5) is a novel IgG receptor. We reported that IgG2 samples display a thousand-fold range affinity for FCRL5, indicating that attributes beyond the isotype affect binding. We hypothesized that the complex interaction could be exploited to identify distinct changes in the IgG2 molecule. We investigated using surface plasmon resonance two factors that might affect the interaction between IgG2 and FCRL5; heterogeneity related to disulfide isoforms and charge variants. We found that panitumumab and denosumab samples enriched for the more flexible A disulfide isoform bound FCRL5 with two-fold and 82-fold higher apparent affinity, respectively, than the B isoform...
November 1, 2017: Molecular Immunology
https://www.readbyqxmd.com/read/29100167/early-identification-and-intervention-matters-a-comprehensive-review-of-current-evidence-and-recommendations-for-the-monitoring-of-bone-health-in-patients-with-cancer
#18
REVIEW
Thomas Brodowicz, Peyman Hadji, Daniela Niepel, Ingo Diel
Bone metastases are common in patients with advanced solid tumors, and many individuals experience debilitating skeletal-related events (SREs; e.g. pathologic fracture, hypercalcemia, radiotherapy or surgery to bone, and spinal cord compression). These events substantially affect disease outcomes, including survival and quality of life, and healthcare systems. Plain radiography is the most widely used imaging modality for the detection of bone metastases; skeletal scintigraphy, computed tomography, positron emission tomography and magnetic resonance imaging offer greater sensitivity but their use in routine practice is restricted by high costs and limited availability...
October 18, 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29083977/examining-the-effect-of-medication-adherence-on-risk-of-subsequent-fracture-among-women-with-a-fragility-fracture-in-the-u-s-medicare-population
#19
Allison Keshishian, Natalie Boytsov, Russel Burge, Kelly Krohn, Louise Lombard, Xiang Zhang, Lin Xie, Onur Baser
BACKGROUND: In the United States, osteoporosis affects approximately 10 million people, of whom 80% are women, and it contributes a significant clinical burden to the community. Poor adherence to osteoporosis medications adds to the overall burden of illness. OBJECTIVE: To examine the association of osteoporosis medication adherence and the risk of a subsequent fracture among Medicare-enrolled women with a previous fragility fracture. METHODS: This study was a retrospective observational analysis of U...
November 2017: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29082518/bisphosphonates-and-other-bone-agents-for-breast-cancer
#20
REVIEW
Brent O'Carrigan, Matthew Hf Wong, Melina L Willson, Martin R Stockler, Nick Pavlakis, Annabel Goodwin
BACKGROUND: Bone is the most common site of metastatic disease associated with breast cancer (BC). Bisphosphonates inhibit osteoclast-mediated bone resorption, and novel targeted therapies such as denosumab inhibit other key bone metabolism pathways. We have studied these agents in both early breast cancer and advanced breast cancer settings. This is an update of the review originally published in 2002 and subsequently updated in 2005 and 2012. OBJECTIVES: To assess the effects of bisphosphonates and other bone agents in addition to anti-cancer treatment: (i) in women with early breast cancer (EBC); (ii) in women with advanced breast cancer without bone metastases (ABC); and (iii) in women with metastatic breast cancer and bone metastases (BCBM)...
October 30, 2017: Cochrane Database of Systematic Reviews
keyword
keyword
8329
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"